MENU
ERAS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Erasca (ERAS) Ownership - Who owns Erasca?
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more
Profile
Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
126
Web
https://www.erasca.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
453.87M
P/E Ratio
N/A
Total Cash
300.66M
Projected Growth
N/A
Total Debt
49.42M
Revenue
N/A
Risk (Beta)
0.87
Dividend Yield
N/A
Total Cash/Share
1.06
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
ERAS
Capitalization
454M
P/E Ratio
N/A
Risk (Beta)
0.87
Dividend Yield
N/A
Total Cash
301M
Total Cash/Share
1.06
Total Debt
49.4M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
372M
P/B Ratio
1.22
Cash Flow
N/A
Earnings
-0.39
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
28K
Current Ratio
11.04
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-135.93M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-26.42
Shares Held By Institutions
360M
Shares Outstanding - Current
284M
Total Liabilities
73.1M
Total Volume MTD
N/A
Value
1
Gain YTD
-36.255
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ERAS showed earnings on August 12, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
126
Web
https://www.erasca.com